Picture of Medacta SA logo

MOVE — Medacta SA News Story

0.000.00%
ch flag iconLast trade - 00:00
HealthcareBalancedMid CapFalling Star

Switzerland's Medacta FY revenue rises, profit up on Parcus Medical acquisition

Overview

Switzerland medical device maker's FY 2025 revenue rose 18.5% in constant currency

Adjusted EBITDA grew 19.1% and margin advanced to 29.0% in constant currency

Net profit increased 31% yr/yr, including one-off gains from Parcus Medical acquisition

Outlook

Medacta targets 2026 revenue growth of 10% to 14% in constant currency

Company expects 2026 adjusted EBITDA margin to expand by around 50bps vs. prior year

Medacta sees mid-term revenue CAGR of 12% to 15% in constant currency through 2027

Result Drivers

INNOVATION & SALES FORCE - Co said revenue growth was driven by ongoing product innovation, expanded sales force, and medical education efforts

PRODUCT LINE GROWTH - Strong revenue growth in Knee, Hip, Extremities, and Spine segments, with Extremities up 46.2% in c.c.

MARGIN EXPANSION - Adjusted EBITDA margin improved due to efficiency gains and lower sales and marketing costs

Company press release: ID:nEQ8rcP4Ba

Key Details

MetricBeat/MissActualConsensus Estimate
FY Adjusted EBITDAEUR 190.80 mln
FY Adjusted EBITDA Margin29.00%
FY Adjusted Free Cash FlowEUR 152.70 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Medacta SA

See all news